Researchers Identify Cell Responsible for Retinoblastoma
A study conducted at St Jude Children’s Research Hospital has identified mature nerve cells which can cause retinoblastoma, a form of eye cancer that normally strikes children under three years of age. The St Jude research team, led by Michael Dyer, PhD, arrived at their discovery by testing different populations of mice whose retinas lacked [...]
click here to read full article...Duke’s Drug Combo Could Treat a Resistant Melanoma
Researchers at Duke University’s Comprehensive Cancer Center have come up with a drug combination which may provide an effective treatment option for metastatic uveal melanoma, a rare and therapy-resistant form of cancer that originates in the colored part of the eye and spreads to other organs. The team’s promising drug duo consists of decitabine and [...]
click here to read full article...Pacific Northwest Prepares for First Proton Therapy Center
The Swedish Cancer Institute (SCI) has announced plans to open a 22 million dollar Proton Beam Radiation Therapy (PBRT) treatment facility which will be the first one of its kind in the Pacific Northwest. PBRT is designed to target tumors that are in close proximity to critical body structures. It is currently used to treat [...]
click here to read full article...Five Year Old Eye Cancer Survivor Excels At Golf
CBS News offers this story about five-year-old eye cancer survivor Kyle Lograsso and his special talent for golf. YouTube Enclosure The HBO series Real Sports also ran a story on Kyle this month. Tags: retinoblastoma
click here to read full article...Avastin Improves Prognosis for Patients with Radiation Retinopathy
According to a two-year study published in the June 2007 edition of Archives of Ophthamology, many patients facing the prospect of blindness due to radiation retinopathy may get to keep their sight longer by using a localized treatment of the well known cancer drug Avastin. Dr Paul T. Finger, Director of Ocular Tumor Services at [...]
click here to read full article...
